A Phase I Study of SRF231 Immunotherapy in Patients with Advanced Solid and Hematologic Cancers


Full Title

A Phase 1 Study of SRF231 in Patients with Advanced Solid and Hematologic Cancers


The purpose of this study is to find the highest dose of the investigational immunotherapy SRF231 that can be given safely in patients with advanced solid tumors or blood cancers that have continued to grow despite prior treatment. SRF231 is designed to target and block a protein on cancer cells called CD47, which cancer cells use to evade detection by the immune system. Inhibiting CD47 boosts the power of the immune system to find and kill cancer cells. SRF231 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor or blood cancer that continued to grow despite treatment.
  • Patients should recover from the serious side effects of previous therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Schram at 646-888-5388.





Disease Status

Relapsed or Refractory